Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$CTXR NEWS! Citius Pharmaceuticals, Inc.'s (NASDAQ:CTXR) Shift From Loss To Profit https://finance.yahoo.com/news/citius-pharmaceuticals-inc-nasdaq-ctxr-113407963.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @Yahoo
Very cheap down here, everything else too, Lol
$CTXR
Nice news out this morning: May 6, 2022 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced that it has selected Biorasi, LLC ("Biorasi"), a global clinical research organization (CRO), to help expand the Company's Phase 3 Mino-Lok trial to additional sites outside the United States. If approved, Mino-Lok would be the first-and-only antibiotic lock solution FDA-approved to salvage infected central venous catheters (CVCs) causing catheter-related blood stream infections (CRBSIs).
"Citius is pleased to collaborate with Biorasi to expand the Mino-Lok trial to include international clinical sites, as originally planned. This complements efforts underway in the U.S. by our lead CRO, Medpace, to drive recruitment. We paused our ex-U.S. strategy as COVID-19 spread across the globe and hospitals halted non-COVID trials. With the COVID-19 pandemic receding, we believe there is now an opportunity to access additional sites and plan to leverage Biorasi's track record of quickly ramping up sites around the world to recruit clinical trial subjects outside the U.S. CRBSIs remain a critical unmet need globally with millions of patients requiring sterile central venous catheters to receive life-saving therapies," stated Leonard Mazur, Chairman and CEO of Citius.
The second half of the year will be very interesting .
Recent Highlights and Upcoming Milestones
Citius anticipates filing a biologics license application (BLA) for I/ONTAK® with the U.S. Food and Drug Administration (FDA) in the second half of 2022;
Topline data from the Phase 3 study of cancer immunotherapy I/ONTAK are consistent with the previously-approved formulation of denileukin diftitox (ONTAK), and there are no new safety signals;
Halo-Lido Phase 2b trial initiated in April 2022 with last patient enrollment anticipated by the end of 2022;
Phase 3 Mino-Lok® trial proceeding without modification as recommended by the independent data monitoring committee (DMC) following all three DMC reviews;
Mino-Lok Phase 3 trial completion anticipated by end of 2022; and,
Pre-clinical development ongoing for Citius' Mino-Wrap and induced mesenchymal stem cell programs.
Dump city, a new 52WL on the way, unlimited supply !!!
Huge dump today, with no bid support looks like somebody needs his salary, end of the month .
How much dilution will take place to support CEO salary of 450k plus 50% of that as a bonus ... before sales from approval of late stage 3 programs kick in? I sold half of my position today and will let the remainder lay dormant.
Important 8K filing today.
well worth the read
https://ih.advfn.com/stock-market/NASDAQ/citius-pharmaceuticals-CTXR/stock-news/87825143/current-report-filing-8-k
Right, my bad. I was just saying in general it's been a tough road.
I'm pretty stunned at this drop. IMO it makes absolutely zero sense, but you just wonder if investors are in overall flight mode, scarred by losses. Psychology plays a big role in all of this as usual.
I just want to clarify this is not an OTC stock. CTXR is listed on the NASDAQ. Big difference
Yep. $$$CTXR$$$ GLTUA
That's how I'm seeing it - I'm not sell Jack S, and if people completely panic I may add.
The pipeline just has too many possibilities. Again - all it takes is one FDA approval. They're in Phase 3 on two big ones - I love our odds here, JMO.
But we're still good here for the longer term.
Yeah understand, I've made the mistake several times through the past 6 months or so with a bunch of stocks in OTC unfortunately.
Yep, wish I wasn't in such a hurry to buy PM when I saw it was dropping.
Well this mornings sales up above 2.25 were a gift for us. Sold over 50000 shares and the buyers wanted them bad for pre mkt. I just bot a chunk back under 1.69. Funny I guess the early worm does get the golden worm. Under 1.70 I feel its a gift again. I am in this for the long term and to see their other products bring revenues. I buy when stocks go on sale and under 1.70 imo its a fire sale lol. Good luck
Interesting - I mean, can you imagine what it would mean if this and/or Mino-Lok was approved? Two gigantic applications...and yet here we are, busting through 1.70. Unbelievably tempting buy here.
I have read where it's a better, more purified version of the ONTAK they already have on the market.
I just woke up from a nap and surprise! This thing dropped even lower. I was expecting a sure rebound with the news. Must be a short attack I suppose.
MORE CATALYSTS COMING
https://seekingalpha.com/article/4498156-citius-2022-is-a-year-of-catalysts
Cheers!
Ridiculous. People are just panic machines these days - they sold it UNDER what it was with the good news lol...I actually thought this could happen. Absolutely insane. To say it's a diluting pig is absolute nonsense. Don't listen to that - 200 million AS is a very small share structure. If (and it's a big IF still) this got FDA approval, $20 would be in play over time IMO.
Diluted Pig is why!
I don't understand. Why the selling?
Incredible....and now panic in PM....people are very finnicky these days. Imagine if they sell it below 1.80 lol...nothing surprises me anymore. 4.7 mil unreal.
Lol, 3 times their daily average pm
Boring morning....only 3.9 million shares traded 85 minutes before the market opens. Yawn. :)
Very nice news this morning. Sold out some shares but will buy them back on any dip under 2.10 just to ring the register agin. I am still looking to fill the gap. Have a great day
The author is susihiman; pumps and dumps stocks. CTXR doesn't deserve a shareholder like him, but it is what it is. If you question him he gets angry and blocks you on stocktwits. He made a lot of money on the last run promising a halt on Mino-Lok and then blames management.
That’s an opinion stated in the article by the author. There has been nothing from the company that says data will be out in April. The only thing they have said is Q2
Murocman
NEW PT OF $10
This article says data will be out in April and issues a PT of $10
https://seekingalpha.com/article/4498156-citius-2022-is-a-year-of-catalysts
NEW APPLICATION PROCESSING 2022-03-18 (filed 3/15/2022)
https://uspto.report/TM/97312597
You seem to hit that $1.80 range well. Congrats. I started adding again and won't sell until $4+ range. Plus long term gains
We took some profit today on 100k shares between 1.79 and 1.80. the mkt absorbed those shares very well .I told him to hold the other 100k and lets see how this plays out. There is a .30 cushion to play with now. Good luck CTXR there is a gap between 2.40 and 2.55 you never know if there is enough good news to power up there but that is what Im looking for.
I have been adding for a year +. I'm close to 90k shares. I'm not to worried about the price, but it is nice being green again.
hopefully not the end of the move up we still hold 40k shares. We were buyers when it got hit under 1.50. I like the company but not crazy about the stock price YET
Probably a good idea. I couldn't do it. Still in my add zone
took some profit today 1.83 Its perking up the
Moving right along- what I didnt like is this statement-"This should be a time when Mino-Lok is needed the most not next yr.
""Covid-19 continues to pose a challenge to the Mino-Lok® Phase 3 trial. We remain committed to completing the trial this year and believe we are well-positioned to continue our efforts as Covid-19 infections and hospitalizations subside, restrictions are lifted and the overall environment for clinical trials improves. These efforts include active engagement with our existing sites, and evaluation of additional trial sites. We continue to believe that there is a significant unmet medical need to salvage catheters so that critically ill patients need not undergo the painful and costly removal and replacement of a central venous line. Our primary focus remains to execute a plan that ensures we have a robust dataset that maximizes the potential success of Mino-Lok®," added Mr. Holubiak."
Starting to perk up CTXR we took a large position after it got hit in Jan lets see where this takes us. Earnings will be out next week maybe a good surprise will get this going
CTXR has been dead in the water for a while now. I'm wondering if the right news can push this one into the $2.50-3.00 range.
This is a real biotech company but not the other scam company. I like this one as well
It has a long ways to go for those people who bought in back when they did a reverse split. Lot's of investors bought in at $7/share. At that time people were pumping $10/share. Time will tell but those investors haven't forgotten.
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on the development and commercialization of first-in-class critical care products, with a pipeline of anti-infectives in adjunct cancer care, oncology, stem cell therapy and unique prescription products.
I feel it will be a big winner coming into the new yr.
Followers
|
89
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
640
|
Created
|
06/05/12
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |